Renal hemodynamic effects of relaxin in humans.
Rat studies have convincingly demonstrated the essential role of the ovarian hormone relaxin in mediating gestational renal hemodynamic and osmoregulatory changes in that species. We describe a model in nonpregnant volunteers using exogenous hCG to stimulate the production and release of ovarian relaxin in order to assess renal hemodynamic responses. Women (n = 10) were serially studied +/- hCG stimulation during menstrual cycles with measurement of inulin, PAH, and neutral dextran clearances (to determine glomerular filtration rate [GFR], renal plasma flow [RPF], and glomerular porosity, respectively). Controls were women without ovarian function (n = 6) and men (n = 10). GFR and RPF were increased in the luteal phase compared to the follicular phase (15.3% increase in GFR, P < 0.005; 17.8% increase in RPF, P < 0.05). In controls, GFR and RPF were not significantly different between study occasions. Although exogenous hCG did not stimulate relaxin secretion in women without ovarian function or in men, it did so in normal women, but not into the pregnancy range. In no group were renal hemodynamics augmented by administered hCG. In naturally occurring cycles, increased serum relaxin is associated with augmented renal hemodynamics. As luteal stimulation with hCG failed to yield pregnancy relaxin levels, the use of exogenous relaxin for human administration is needed to further elucidate the renal vasodilatory properties of relaxin.
Smith
Marie
M
School of Surgical and Reproductive Sciences (Obstetrics & Gynaecology), University of Newcastle upon Tyne, NE2 4HH, UK. m.c.smith@ncl.ac.uk
Davison
John
J
Conrad
Kirk
K
Danielson
Lee
L
D000293:Adolescent; D000328:Adult; D004967:Estrogens / Q000097:blood; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007668:Kidney / Q000098:blood supply / Q000187:drug effects* / Q000502:physiology*; D008297:Male; D008597:Menstrual Cycle / Q000187:drug effects / Q000502:physiology; D010053:Ovary / Q000002:abnormalities / Q000187:drug effects / Q000502:physiology / Q000503:physiopathology; D016649:Primary Ovarian Insufficiency / Q000150:complications / Q000503:physiopathology; D012065:Relaxin / Q000378:metabolism / Q000494:pharmacology*
D004967:Estrogens; D012065:Relaxin